Every month I try to read an open-access article. Then, I share the title and associated link with my followers. This is to encourage clinicians to read articles, stay up to date, and continue to grow.
The objective of this month’s paper is to evaluate “the dose-exposure and safety of nintedanib in children and adolescents with fibrosing ILD” (p2).
Nintedanib in children and adolescents with fibrosing interstitial lung diseases
By: Robin Deterding, Lisa R. Young, Emily M. DeBoer, David Warburton, Steven Cunningham, Nicolaus Schwerk, Kevin R. Flaherty, Kevin K. Brown, Mihaela Dumistracel, Elvira Erhardt, Julia Bertulis, Martina Gahlemann, Susanne Stowasser, and Matthias Griese for the InPedILD trial investigators.
European Respiratory Journal 2023 61: 2201512;
Link to the article: https://erj.ersjournals.com/content/61/2/2201512
“ The results demonstrated that nintedanib had an acceptable safety profile in this patient population. “page 8
“..the pharmacokinetic data from the InPedILD trial show that the weight-based dosing regimen achieved exposure in paediatric patients that was comparable to that observed in adults treated with 150 mg twice daily, supporting the use of this dosing regimen in the paediatric population.”page 8
Happy reading and learning,
Feb. 15th, 2023